Roberto Lopez-Alberola
Neurology with Special Qualifications in Child Neurology · Miami, FLNPI 1417977554
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 28.5% of the total. 2025 is the largest year on record at $8,730, 4.9 times the $1,795 reported in 2019.
Across 151 payments — averaging $202.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$9K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$8K
- Biogen$5K
- Livanova USA, Inc.$5K
- Vertex$1K
- Jazz Pharmaceuticals Inc.$511
- plus $3K from 21 others
Across 1 payment — averaging $3164.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$3K
What the payments were for
- Consulting fees$11,04036%
- Speaking & faculty fees$9,02430%
- Travel & lodging$4,48315%
- Food & beverage$6,01120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 16 | $8,713 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 6 | $8,092 |
| Biogen | 16 | $4,779 |
| Livanova USA, Inc. | 21 | $4,709 |
| Vertex | 2 | $1,050 |
| Jazz Pharmaceuticals Inc. | 18 | $511 |
| Neurelis, Inc. | 21 | $426 |
| UCB, Inc. | 8 | $400 |
| Genentech USA, Inc. | 12 | $267 |
| Novo Nordisk | 2 | $248 |
| AstraZeneca | 2 | $230 |
| AbbVie(2 entities) | 5 | $186 |
| Medtronic | 1 | $171 |
| Novartis | 2 | $144 |
| NS Pharma, Inc. | 4 | $131 |
| Baudax Bio Inc. | 1 | $124 |
| Biomarin Pharmaceutical Inc. | 1 | $74 |
| Catalyst Pharmaceuticals, Inc. | 2 | $54 |
| Eagle Pharmaceuticals, Inc. | 2 | $44 |
| ITF Therapeutics LLC | 2 | $39 |
| Pfizer | 1 | $36 |
| Sanofi | 1 | $31 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Greenwich Biosciences, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,558 in reported general payments places this provider in the 85th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 12 | $2,204 |
| Clonazepam | 29 | $930 |
| Risperidone | 11 | $145 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Miami
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ian MillerMiami$104K
- Matt LallasMiami$88K
- Marytery FajardoMiami$44K
- Paula SchleiferMiami$31K
- Anuj JayakarMiami$24K
- Walter BradleyMiami$19K
- Yashira Torres RamirezMiami$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.